|
WO2019145571A1
|
|
Bifidobacterium longum ncimb 41676
|
|
WO2019145574A1
|
|
Bifidobacterium longum ncimb 41676
|
|
CA3054099A1
|
|
Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
|
|
CN110392734A
|
|
It can valuably bifidobacterium longum of the metering needle to the immune response of respiratory virus infection
|
|
WO2017097987A1
|
|
Bifidobacterium longum for treating obesity and associated metabolic disorders
|
|
CN109312297A
|
|
For treating the Lactobacillus casei of obesity and associated metabolic disease
|
|
US2018280453A1
|
|
Use of bifidobacterium longum and an exopolysaccharide produced thereby
|
|
AU2016312624A1
|
|
Bifidobacterium longum
|
|
AU2016206219A1
|
|
Bifidobacterium longum
|
|
AU2015201431A1
|
|
Bifidobacterium longum
|
|
WO2012140636A1
|
|
A probiotic formulation
|
|
AU2011205121A1
|
|
Method of use of orally administered probiotic bifidobacteria for human beauty benefits
|
|
AU2011202947A1
|
|
Feline probiotic lactobacilli
|
|
BR112012011315A2
|
|
probiotic bifidobacterial strain
|
|
EP2498790A1
|
|
A bifidobacterium strain
|
|
AU2009315298A1
|
|
Bifidobacterium longum
|
|
WO2010049921A1
|
|
Disaccharides
|
|
IE20090847A1
|
|
A synthesized disaccharide exhibiting immunomodulatory activity
|
|
WO2009043856A2
|
|
Modulation of tissue fatty acid composition of a host by human gut bacteria
|
|
CN101835806A
|
|
An exopolysaccharide
|
